This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

ViewRay Gestione

Gestione criteri di controllo 1/4

ViewRay Il CEO è Paul Ziegler, nominato in Jul2023, ha un mandato di meno di un anno. possiede direttamente 0.039% delle azioni della società, per un valore di € 6.81. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 0.7 anni e 3.5 anni.

Informazioni chiave

Paul Ziegler

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	0.04%
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	3.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Paul Ziegler rispetto agli utili di ViewRay?
Data	Compenso totale	Stipendio	Guadagni aziendali
Mar 31 2023	n/a	n/a	-US$110m
Dec 31 2022	n/a	n/a	-US$107m
Sep 30 2022	n/a	n/a	-US$107m
Jun 30 2022	n/a	n/a	-US$106m
Mar 31 2022	n/a	n/a	-US$109m
Dec 31 2021	US$2m	US$350k	-US$110m

Compensazione vs Mercato: Dati insufficienti per stabilire se la retribuzione totale di Paul sia ragionevole rispetto ad aziende di dimensioni simili nel mercato German.

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Paul con le performance aziendali.

AMMINISTRATORE DELEGATO

Paul Ziegler (50 yo)

less than a year

Mandato

US$2,028,555

Compensazione

Mr. Paul Ziegler. Jr., J.D., serves as President, Chief Executive Officer and Director at ViewRay, Inc. since July 2023 and was its Chief Commercial Officer since 2021 until July 2023 and served as its Exe...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Paul Ziegler	President	less than a year	US$2.03m	0.039% € 6.8
James Dempsey	Founder & Chief Scientific Officer	19.6yrs	US$1.17m	0.16% € 28.3
Jacob Signoriello	Interim Chief Financial Officer	less than a year	Nessun dato	Nessun dato
Drew Hill	Senior Vice President of Operations & Development	1.8yrs	Nessun dato	Nessun dato
Matt Harrison	Director of Investor Relations	no data	Nessun dato	Nessun dato
Sanket Shah	Senior VP & General Counsel	less than a year	Nessun dato	0.21% € 36.6
Karen Hackstaff	Vice President of Marketing	no data	Nessun dato	Nessun dato
Julianne Mast	Vice President of Human Resources	less than a year	Nessun dato	Nessun dato
Martin Fuss	Chief Medical Officer	no data	Nessun dato	Nessun dato
Adam Podbelski	Senior Vice President of Commercial Operations	1.8yrs	Nessun dato	0.24% € 42.3
Steven Annen	Senior Vice President of Global Marketing	less than a year	Nessun dato	Nessun dato
Ashley Kluth	Senior Manager of Investor Relations	no data	Nessun dato	Nessun dato

0.7yrs

Durata media

52yo

Età media

Gestione esperta: Il team dirigenziale di 6L9 non è considerato esperto (durata media 0.7 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Paul Ziegler	President	less than a year	US$2.03m	0.039% € 6.8
Caley Castelein	Independent Director	15.8yrs	US$212.17k	0.027% € 4.7
B. Johnson	Independent Director	3.5yrs	US$208.00k	0.092% € 15.9
Brian Roberts	Independent Director	7.8yrs	US$221.00k	0.065% € 11.4
Daniel Moore	Independent Chairman	5.7yrs	US$261.00k	0.11% € 19.0
Scott Drake	Director	5.3yrs	US$5.80m	0.32% € 56.1
Karen Prange	Independent Director	2.3yrs	US$201.00k	0% € 0
Stefanie Corradini	Member of Medical Advisory Board	no data	Nessun dato	Nessun dato
Enis Ozyar	Member of Medical Advisory Board	no data	Nessun dato	Nessun dato
James Good	Member of Medical Advisory Board	no data	Nessun dato	Nessun dato
Lauren Henke	Member of Medical Advisory Board	less than a year	Nessun dato	Nessun dato
Rupesh Kotecha	Member of Medical Advisory Board	less than a year	Nessun dato	Nessun dato

3.5yrs

Durata media

55yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 6L9 sono considerati esperti (durata media dell'incarico 3.5 anni).

This company is no longer active

ViewRay Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

ViewRay, Inc. Announces the Resignation of Sai Nanduri as Observer to the Board

Viewray, Inc. Announces Resignation of Susan Schnabel from Board of Directors

ViewRay, Inc. Appoints Sai Nanduri as an Observer of the Board of Directors

ViewRay, Inc. Announces CFO Changes

Insider recently bought €113k worth of stock

President recently bought €379k worth of stock

Recent updates

Motion For Case Conversion Approved for ViewRay, Inc.

Nasdaq To Delist the Common Stock of ViewRay

ViewRay, Inc.(OTCPK:VRAY.Q) dropped from NASDAQ Composite Index

ViewRay Announces Commencement of Nasdaq Delisting Proceedings

ViewRay, Inc. Announces the Resignation of Sai Nanduri as Observer to the Board

Motion for Joint Administration Filed by ViewRay, Inc.

Viewray, Inc. Announces Resignation of Susan Schnabel from Board of Directors

ViewRay Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.14 loss in 1Q 2022)

ViewRay, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings released: US$0.59 loss per share (vs US$0.67 loss in FY 2021)

ViewRay, Inc. to Report Q4, 2022 Results on Feb 27, 2023

ViewRay, Inc. Appoints Sai Nanduri as an Observer of the Board of Directors

ViewRay, Inc. Announces Findings from the Phase III Randomized Controlled Mirage Trial

ViewRay, Inc. Announces CFO Changes

Insider recently bought €113k worth of stock

Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.15 loss in 3Q 2021)

ViewRay, Inc. Provides Revenue Guidance for the Full Year 2022

ViewRay, Inc Announces the Final Primary Endpoint Results from the Phase III Randomized Single-Center MIRAGE Trial

ViewRay, Inc Announces the Final Primary Endpoint Results from the Phase III Randomized Single-Center MIRAGE Trial

ViewRay, Inc. Announces Primary Endpoint Outcome from First Prospective, Multi-Institutional Study to Deliver Ablative Doses of Radiation to Pancreatic Cancer Patients

ViewRay, Inc. Launches Phase III Pancreatic Cancer Study to Demonstrate Superior Overall Survival for Patients Receiving MRI-guided Ablative Radiation Therapy

ViewRay, Inc. to Report Q3, 2022 Results on Nov 01, 2022

ViewRay Announces China NMPA Approval of its MRIdian(R) MRI-Guided Radiation Therapy for Cancer Patients

ViewRay, Inc. Selects Denver for Headquarters

Second quarter 2022 earnings released: US$0.15 loss per share (vs US$0.19 loss in 2Q 2021)

Viewray, Inc. Updates Earnings Guidance for the Year 2022

ViewRay, Inc. to Report Q2, 2022 Results on Aug 02, 2022

President recently bought €379k worth of stock

First quarter 2022 earnings released: US$0.14 loss per share (vs US$0.17 loss in 1Q 2021)

ViewRay, Inc. Reiterates Earnings Guidance for the Year 2022

ViewRay, Inc., Annual General Meeting, Jun 10, 2022

ViewRay, Inc. to Report Q1, 2022 Results on May 05, 2022

Insider recently bought €88k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Viewray, Inc. Provides Revenue Guidance for the Year 2022

ViewRay Announces Interim Findings from MIRAGE Phase III Randomized Trial Signal Superiority of MRIdian® MRI-guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer

ViewRay, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Chief Financial Officer recently bought €88k worth of stock

Chief Financial Officer recently bought €181k worth of stock

Second quarter 2021 earnings released: US$0.19 loss per share (vs US$0.18 loss in 2Q 2020)

ViewRay, Inc.(NasdaqGM:VRAY) dropped from Russell Microcap Value Index

ViewRay, Inc. Not to Provide Financial Guidance

First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.19 loss in 1Q 2020)

Chief Operating Officer has left the company

ViewRay, Inc. Announces the Resignation of Shahriar Matin as Chief Operating Officer, Effective from March 31, 2021

Full year 2020 earnings released: US$0.73 loss per share (vs US$1.18 loss in FY 2019)

Revenue beats expectations

ViewRay, Inc. to Report Q4, 2020 Results on Mar 04, 2021

Independent Director has left the company

ViewRay, Inc. Announces Retirement of D. Keith Grossman from Board of Directors

Viewray, Inc. Appoints Phil Spencer to Its Board of Directors

Edogawa Hospital in Tokyo Installs Japan's First ViewRay MRIdian Linac

The Henry Ford Cancer Institute Installs Its Second Viewray Mridian® Linac

An unknown buyer acquired 7.3% stake in ViewRay, Inc. (NasdaqGM:VRAY) from Elekta AB (publ) (OM:EKTA B) for $53.5 million.

ViewRay, Inc. has completed a Follow-on Equity Offering in the amount of $50.0035 million.

New 90-day high: €4.22

New 90-day high: €3.68

New 90-day high: €3.26

President recently bought €423k worth of stock

Universitair Ziekenhuis Brussels Purchases ViewRay's MRIdian Linac

Third quarter 2020 earnings released: US$0.19 loss per share

Revenue beats expectations

ViewRay, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day high - €3.00

ViewRay, Inc. to Report Q2, 2020 Results on Jul 30, 2020

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO